DHB
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
DHB is a dry injectable AAS for advanced users chasing lean-mass gain, hardness, vascularity, and strength endurance without estrogen-driven water retention; the tradeoff is unusually high injection, inflammation, mood, and sourcing tax.
Expect significant post-injection pain, CRP elevation, hematocrit and BP drift, and unmasked scalp hair loss that finasteride cannot prevent — monitor lipids, CBC, hsCRP, BP, and LFTs at baseline and midcycle, and discontinue if hsCRP climbs above 10 mg/L or hematocrit clears 54%.
DHB is a dry injectable AAS for advanced users chasing lean-mass gain, hardness, vascularity, and strength endurance without estrogen-driven water retention; the tradeoff is unusually high injection, inflammation, mood, and sourcing tax.
Severe site-dependent post-injection pain, elevated hsCRP and flu-like malaise in a subset of users, hematocrit and lipid skew, hairline recession, and mood flatness or depression that can appear within weeks even at modest doses.
Mid-tier value — material cost $30-60/week at typical 300-500 mg/week dosing; cheaper than pharma Primobolan supply but more expensive than testosterone, and tolerability failures waste vials.
Polarized: roughly 40% report a 'great dry compound' experience, 30% report 'good gains but intolerable pain', 20% report mood flatness or depression, and 10% suspect they received fake or substituted product. Product identity and batch consistency dominate outcomes.
Do not stack with trenbolone at full doses — overlapping androgen-receptor saturation and CNS side effects, with diminishing incremental gain and additive cardiovascular load.
Intro
Dihydroboldenone is a synthetic anabolic-androgenic steroid, structurally the 5α-reduced metabolite of boldenone — analogous to how dihydrotestosterone is the 5α-reduced metabolite of testosterone.
The molecule is alternately called 1-Testosterone or δ¹-dihydrotestosterone, with the '1-' referring to a double bond between carbons one and two replacing testosterone's standard 4(5)-double bond. The cypionate ester is the dominant injectable form in community use; acetate exists but is rare. The compound binds the androgen receptor with potency comparable to testosterone but cannot aromatize to estrogen, cannot be further reduced by 5α-reductase, and cannot be blocked at the scalp by finasteride or dutasteride.
The compound has existed in steroid literature since the 1960s but never reached therapeutic use because its efficacy at human doses did not justify its side-effect profile in early evaluation. Community adoption is recent — underground production at scale only began around 2018, driven by the collapse of reliable pharma-grade Primobolan supply and the rising counterfeit rate on what little remained. The dominant adoption framing is 'poor man's primobolan' or 'diet trenbolone': users running 300-500 mg per week on a testosterone base consistently report dry, hard, vascular recomposition with the aesthetic signature that Primobolan made famous, without the supply gamble.
Clinical literature is sparse. Friedel et al. published a 2006 toxicology paper describing high AR binding affinity and androgenic activity in vivo without estrogenic effects. Most other published references are older characterization papers from the 1960s-70s. There is no therapeutic indication and no controlled human trial. Critical editorial coverage characterizes the compound as overhyped relative to its actual evidence base, with the frequently-cited 200:100 anabolic-to-androgenic ratio originating from rodent assays that do not translate directly to human dose-response.
The community treats dihydroboldenone as a secondary injectable for intermediate-to-advanced users who have already characterized their personal AR sensitivity on testosterone. Beginner use is widely discouraged across community and practitioner discussion — not because of acute toxicity, but because tolerance to the dominant side effect, post-injection pain, varies dramatically between users and between vials, and most first-time users overdose chasing trenbolone-like results before stabilizing on a sustainable protocol.
Observed Effects
Primary intended effects. Users running 300-500 mg per week on a testosterone base of 150-300 mg per week consistently report dry, hard, vascular physique changes appearing at week 4-6, with peak effect at week 8-10.
The aesthetic is comparable to Primobolan: no water retention, pronounced vascularity, hardness over volume. Strength gains track session-over-session through the cycle, with multiple community logs reporting personal records on barbell and dumbbell lifts even in caloric deficit. Lean-mass accrual is slower than the same milligram dose of testosterone or trenbolone but persists without the water-weight inflation that test produces.
Secondary effects. Increased body temperature and night sweats are commonly reported, with a thermogenic feel that one practitioner analysis described as similar to but less intense than trenbolone. Muscular endurance and cardiovascular endurance reportedly improve more than expected for an AR-driven compound, possibly through hematocrit-mediated oxygen carrying capacity. Libido is reported as 'pretty insane' by experienced users, consistent with elevated total androgen activity.
Timeline. Cypionate ester's ~8-day half-life means peak serum concentrations are reached at 48 hours post-injection and active duration runs ~192 hours. Steady-state requires 4-5 weeks. Users running cycles shorter than 10 weeks routinely report 'feels weak' — the kinetics simply do not deliver until midcycle. Kickstart compounds (Tbol, Anavar, Test Prop) are commonly added for the first 4 weeks to bridge the slow onset.
What didn't work. Multiple users report the compound 'doing nothing' at 200-300 mg per week and concluding it was fake or under-dosed, only to learn the dose was simply insufficient or the cycle was too short. A counter-pattern: users reporting strong effects at 200 mg per week alongside other compounds attribute the effects to dihydroboldenone when the testosterone or trenbolone alongside it was doing the work. Batch-to-batch consistency is poor, and the same user can experience dramatically different effects from two vials of the same product.
Stack-position observation. Multiple community sources describe trenbolone overshadowing dihydroboldenone at standard cycle doses — the AR-saturation surfaces overlap enough that adding dihydroboldenone on top of trenbolone provides limited incremental benefit at the doses where both are typically run.
Field Reports
What works. Users who succeed with dihydroboldenone characterize their approach narrowly: 300-500 mg per week on a identity-tested product, 2-3 weekly injections at 75-100 mg/mL concentration, glute or ventroglute injection sites, formulation handling discipline, 12-16 week cycle length, biomarker monitoring at baseline and midcycle, kickstart compound for weeks 1-4, full SERM PCT for non-TRT users. A frequently cited community review exemplifies this pattern: dozens of injections, only rare bad PIP events, multiple PR lifts in caloric deficit, and a dry-hard recomp aesthetic.
What doesn't work. Overdosing chasing trenbolone-like results (600-800 mg per week first cycle), pinning quadriceps with short pins (subcutaneous leak guarantees bad PIP), running 200 mg per week for 6 weeks and concluding the compound is fake (kinetics simply haven't stabilized), accepting PIP-absent product as trustworthy (almost certainly counterfeit), pushing through hsCRP elevation above 10 mg/L (the inflammatory load is the compound itself, not a transient adaptation), ignoring early mood-flatness signals (subset of users develop genuine depression that resolves only on discontinuation).
Common mistakes from first-time users. The most common first-time error is over-stacking — adding DHB simultaneously with two or three other unfamiliar compounds, then being unable to attribute side effects when problems emerge. Practitioner consensus is to add one new compound at a time on a known testosterone base. The second most common error is cycle length below 10 weeks; cypionate kinetics need 4-5 weeks to stabilize, and cycles cut at 6-8 weeks deliver only the PIP burden without the recomposition payoff.
How experienced users refine protocols. Veterans typically settle at 300-400 mg per week (not 500+), prefer better-tolerated carrier oils when available, dilute single-shot oil burden when medically appropriate, rotate sites rather than repeatedly stressing one area, and monitor hsCRP and CBC every 6 weeks even during steady-state runs. They also pre-stack supportive lipid and inflammation supplements (citrus bergamot, red yeast rice, ezetimibe, omega-3) from week 1 rather than reactively when bloodwork worsens.
Subjective experience reports. Users describe pronounced vascularity and 'hardness' onset around week 4-6, peak strength endurance week 8-10, libido strongly elevated throughout cycle, body temperature noticeably elevated especially at night, sleep quality unchanged or slightly disrupted, mood variable — some users report feeling great, others describe flatness or 'blues.' The thermogenic feel is real but not as intense as trenbolone. Some users describe the compound as feeling 'mechanically anabolic without the mood high' that testosterone-dominant cycles provide.
Cost-benefit assessment from user perspective. Material cost is mid-tier: $300-720 for a 10-16 week cycle at typical doses, breaking down to $3-7 per day. Cheaper than chasing pharma-grade Primobolan supply, more expensive than testosterone-only cycles. The cost-benefit failure mode is not the dollar cost — it is the wasted vial cost when a user quits at week 3 from PIP and has 4 unopened vials sitting in a drawer. Multiple community sources report 5+ unopened DHB vials in storage from abandoned cycles.
Polarization of perception. The same compound generates 'best compound I've ever run' reports and 'crippling debilitating' abandonment reports in the same community thread, sometimes at the same dose. Personal AR sensitivity, product source batch quality, injection technique, and individual inflammatory susceptibility all contribute. Users cannot predict their personal response without trying — which is why the conservative-starter protocol exists.
Community Consensus
Dihydroboldenone occupies a specific niche in the gray-market AAS landscape: the post-2018 'poor man's Primobolan' option, adopted by advanced users because reliable methenolone supply became scarce and counterfeit-heavy.
The compound was structurally characterized decades earlier but never developed into a therapeutic agent; the current adoption wave is commercial and supply-driven, not clinical.
Community framing splits along two axes. For recreational lean-mass and aesthetic users, Primobolan is usually rated higher on tolerability when supply allows; DHB becomes attractive when cost, authenticity, or access make Primobolan impractical. For post-finasteride syndrome recovery, a niche community protocol ranks DHB above Primobolan and Masteron because 5α-reduced AR activation maps onto the proposed injury pattern. That protocol is experimental and sits outside standard physique use.
The consensus is polarized but not random. Successful users describe a narrow lane: identity-tested product, 300-500 mg per week, 75-100 mg/mL concentration, careful site rotation, vial warming, testosterone base, 12-16 week cycle, and baseline plus midcycle labs. Failed runs usually cluster around crippling PIP, mood flatness, hsCRP elevation, short cycles, overdosing, or suspected counterfeit product. DHB is therefore treated as an advanced-user compound with real dry-recomp payoff only when the user already has AAS experience, bloodwork access, and injection discipline.
Female community use is essentially nonexistent. DHB's high androgenic activity, hairline aggressiveness, and irreversibility profile make it unsuitable for female recreational use; available discussion describes avoidance rather than protocol. Practitioners do not recommend it for women at any dose.
The authenticity problem is central. Counterfeit dihydroboldenone is commonly substituted with boldenone or another ester; 'PIP-absent DHB' is treated as a near-certain counterfeit signal in community wisdom. Users reporting trenbolone-like aggression on apparent DHB should consider trenbolone substitution as an alternative explanation. Product identity and batch consistency are more important than dose selection for most new users.
Risks & Monitoring
Adverse effects cluster around four mechanisms: local inflammation from injection, systemic inflammation, hematocrit/cardiovascular drift, and CNS/mood effects.
Side-effect severity scales with dose, cycle duration, product quality, and personal androgen sensitivity in non-linear ways.
Post-injection pain (PIP). The dominant practical complaint. Most users report 'savage' PIP that can persist 3-7 days at the injection site, with hard induration ('a lump in the glut') developing after repeated use of the same site. Severity is dramatically product source-dependent. Community reports span severe PIP after 200 mg at 100 mg/mL, including inflammatory swelling severe enough to prompt hospital concern, through unusually tolerable runs with only rare bad injections. The pattern: larger glute/ventroglute sites are better tolerated than quadriceps, and short-pin subcutaneous leak is repeatedly blamed for worse PIP.
Pain mechanism is dose-concentration-driven. Tolerable concentrations are 75-100 mg/mL; above 100 mg/mL, even short-term tolerance is rare. A few 150 mg/mL preparations are reported as tolerable, but they are exceptions. Concentrations above 200 mg/mL are universally intolerable. Crashing — recrystallization out of carrier oil — is endemic because dihydroboldenone cypionate has a melting point of 192-196°C, very close to most carrier oils' smoke points. Warming the oil before administration is commonly reported as a tolerability tactic, but it does not remove the underlying formulation problem.
Systemic inflammation and CRP elevation. Practitioner guides flag CRP elevation as a documented signature of dihydroboldenone use, distinct from the local PIP signal. Community discussion attributes this to the compound itself or its metabolites rather than purely to carrier oil reactions. Flu-like malaise — fatigue, low-grade fever, body aches — appears in a subset of users and tracks the CRP rise. One long-term user described developing what was effectively an allergic-type reaction after years of tolerability, 'going from rarely getting PIP to consistently getting reactions at the injection site,' suggesting cumulative sensitization may occur.
Hematocrit, blood pressure, and lipids. Standard DHT-class androgenic effects: hematocrit drifts upward (donations or therapeutic phlebotomy may be needed midcycle), blood pressure trends up consistent with vasoconstriction and volume, lipid panels skew unfavorable (total cholesterol up, HDL down). Some users stack supportive lipid-management supplements (citrus bergamot 1-1.5 g daily, red yeast rice 600 mg, ezetimibe 10 mg) preemptively during cycle.
Hair loss. Dihydroboldenone is already 5α-reduced, so finasteride and dutasteride cannot block its androgen receptor activation at scalp follicles. Users with male-pattern hair loss susceptibility should expect frontal hairline recession at therapeutic doses; topical antiandrogens are the only mitigation strategy that remains available.
CNS and mood effects. Variable and unpredictable. A subset of users — present at doses as low as 200 mg per week — report mood flatness, anhedonia, depression, manic mood swings, or in rare cases active suicidal ideation. One 2024 community report described a user starting 200 mg per week, feeling fine during week one, then developing continuous suicidal thoughts that resolved on discontinuation. Other users at higher doses report no mood effects whatsoever. The mechanism is unclear; one hypothesis is that the CRP-driven cytokine response affects CNS mood regulation in susceptible individuals.
Hepatic effects. Rodent studies document hepatotoxicity. While injectable AAS skip first-pass metabolism, systemic recirculation still encounters hepatic CYP3A4. ALT, AST, and GGT monitoring at baseline and midcycle is prudent, particularly for users stacking with oral kickstart compounds.
HPG axis suppression. Standard for any AR-active compound at supraphysiologic doses. Endogenous testosterone production is suppressed; PCT is required for non-TRT users after cycle. Acid reflux has been reported anecdotally; mechanism is unclear, possibly related to systemic androgen-driven gastric acid stimulation.
Adulteration risk. Counterfeit dihydroboldenone is commonly adulterated with boldenone (equipoise); painless dihydroboldenone is essentially guaranteed to be a substituted product. Community wisdom: 'if there's no PIP, 99.9% it's fake.' Users who report dramatic AR effects on apparent dihydroboldenone alongside aggression spikes should consider trenbolone substitution as the alternative explanation.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Establishes baseline hematocrit, hemoglobin, and red cell indices before DHT-class hematocrit elevation begins. Discontinuation threshold: hematocrit above 54%.
Hematocrit drift is predictable on dihydroboldenone; midcycle CBC catches red cell mass elevation before BP and viscosity issues become symptomatic. Therapeutic phlebotomy or donation may be indicated if hematocrit clears 54%.
DHT-class compounds reliably skew lipids unfavorably. Baseline is needed for discontinuation framing if midcycle values worsen significantly.
Expected pattern: total cholesterol up, HDL down, LDL up. Watch for HDL below 30 mg/dL or LDL above 160 mg/dL — consider supportive supplementation (citrus bergamot, red yeast rice, ezetimibe) or dose reduction.
Dihydroboldenone is associated with systemic CRP elevation distinct from local injection-site inflammation. Baseline above 3 mg/L should make the user reconsider the compound entirely.
If midcycle hsCRP clears 10 mg/L without alternative explanation (infection, dental issue, training injury), the compound is the most likely driver — consider discontinuation. Flu-like malaise often accompanies the elevation.
Establishes renal baseline and broad liver/electrolyte context. Elevated creatinine or low eGFR at baseline is a strong contraindication given the BP and inflammation load.
Rodent literature documents hepatotoxicity. While injectable use mitigates first-pass exposure, systemic recirculation through hepatic CYP3A4 makes baseline and midcycle LFTs prudent — especially when stacked with oral kickstart compounds.
Post-cycle hormonal recovery panel at 3-4 weeks past last cypionate pin. Confirms PCT effectiveness for non-TRT users; documents recovery timeline.
Sustained systolic above 140 mmHg or diastolic above 90 mmHg during cycle is a discontinuation or dose-reduction trigger. Hematocrit-driven viscosity and direct androgenic vasoconstriction both contribute.
Dihydroboldenone does not aromatize, so estradiol management is driven by the testosterone base dose. Midcycle E2 helps calibrate AI dosing off the test, not off the DHB.
Avoid With
Do not combine DHB with the following. Sorted highest-severity first.
Why:In the DHB + sodium valproate PFS recovery protocol, testosterone is intentionally excluded — re-introducing testosterone re-engages the 5α-reductase pathway and can worsen post-finasteride symptoms. This is a niche protocol-specific exclusion, not a general DHB rule.
What to do:For all non-PFS uses, testosterone IS the required base. PFS recovery protocols are highly experimental and outside conventional cycling.
Why:Substantial AR-saturation overlap means combining both at full doses (e.g., 400 mg trenbolone + 500 mg DHB) provides limited incremental benefit while doubling cardiovascular load, CRP burden, scalp impact, and mood side-effect probability. Pick one as primary AR driver.
What to do:If both are used, drop one to a low 'sprinkle' dose (100-200 mg per week) rather than running both at full clinical doses.
Why:Even injectable AAS encounter hepatic CYP3A4 via systemic recirculation. Strong CYP3A4 inhibitors can elevate DHB serum levels unpredictably, compounding side effects. CYP3A4 inducers (St. John's Wort, rifampin) drop serum levels.
What to do:Most users are not running these medications, but stacking polypharmacy on DHB requires checking the interaction surface — practitioner consensus calls CYP3A4 a 'minefield' for stacked supplement and drug regimens.
Why:Stacking three DHT-class compounds piles on hematocrit, BP, scalp, and mood load without proportional anabolic benefit — AR saturation curves flatten at high total androgen load.
What to do:Two DHT-class compounds together is conventional (DHB + Mast, DHB + Primo); three at full doses is excessive.
Why:DHB's documented hepatotoxicity signal in rodent studies plus CRP and lipid burden combined with full-cycle methylated orals dramatically elevates hepatic and cardiometabolic load.
What to do:Short kickstart use (4-6 weeks) of methylated orals is widespread and accepted; long co-administration is not.
Why:Dihydroboldenone is already 5α-reduced. 5α-reductase inhibitors cannot prevent AR activation at scalp follicles by a compound that is already past the 5α-reduction step. Finasteride remains useful for testosterone-derived DHT at scalp, but offers no protection from DHB-driven hair loss.
What to do:Topical antiandrogens (RU-58841, fluridil) remain the only mechanistic option for scalp protection during DHB cycles.
Protocols By Goal
Dry lean-mass / recomp. 300-500 mg per week dihydroboldenone cypionate on 200-300 mg per week testosterone cypionate, 12-16 weeks.
Diet at maintenance to slight surplus (200-300 kcal). Tbol or Anavar kickstart for weeks 1-4 (40-60 mg per day). Biomarker targets: hsCRP below 5 mg/L midcycle, hematocrit below 52%, blood pressure below 135/85, E2 in middle range via AI gated on the test base. Pin schedule: 2x weekly, Mon/Thu.
Cutting and physique sharpening. 200-400 mg per week dihydroboldenone cypionate on testosterone cruise (100-200 mg per week), 10-12 weeks during deficit phase. Caloric deficit 300-500 kcal below maintenance. Possible additions: Anavar 40-50 mg per day at weeks 8-12 for final hardening, or low-dose trenbolone at weeks 8-12 if AR-sensitivity allows. Biomarker focus: hematocrit and lipid stability rather than maximizing mass.
Strength-peaking phase (powerlifting / strength sports). 400-600 mg per week dihydroboldenone cypionate sprinkled on top of an already-stacked cycle (test + trenbolone + DHB) for the final 8-12 weeks before a competition. Dihydroboldenone's contribution here is hardness and aesthetic — the trenbolone or testosterone is doing the primary strength work. This is the application where 'sprinkled on top' framing fits.
Post-finasteride syndrome (PFS) recovery — experimental, niche. 100-200 mg per week dihydroboldenone cypionate combined with sodium valproate, intentionally excluding testosterone. The protocol — described as a 'eureka moment' in community discussion — targets AR re-activation in 5α-reduced tissues without re-engaging the finasteride-injury cascade. Sodium valproate provides HDAC inhibition and GABAergic modulation. This is highly experimental, not a standard protocol, and falls well outside conventional dihydroboldenone use cases. Users pursuing this pathway should work with a knowledgeable practitioner rather than self-administer.
Not appropriate for. Bulking goals (the dry phenotype provides no caloric advantage and the inflammatory load forces diet limitations), beginners (PIP and mood variability require established baseline characterization), users with pre-existing kidney concerns, users with documented hsCRP elevations, users with active hair-loss progression.
Dosing Details
Standard community protocol. Dihydroboldenone cypionate is commonly reported at 300-500 mg per week, split across 2 or 3 weekly injections, on top of a testosterone base of 150-300 mg per week.
The testosterone base appears because DHB does not aromatize and cannot provide E2-mediated libido, joint, or cardiovascular support. Cycle length is usually 10-16 weeks because the cypionate ester does not feel fully developed until midcycle.
Conservative starter. First-time reports often use 200-300 mg per week on a testosterone base to characterize personal PIP tolerance, mood response, and hsCRP sensitivity before committing to a longer course. Multiple practitioner guides frame overdosing DHB as the dominant first-time error.
Aggressive protocol. Experienced-user reports reach 500-700 mg per week, often with a higher testosterone base and sometimes another compound. Daily injection reports exist mainly to manage single-shot oil volume; pharmacokinetically, 2-3 weekly injections are enough for the ester.
Concentration ceiling. 75-100 mg/mL is the commonly tolerated formulation range. 150 mg/mL is a high-end exception in some reports. Above 100 mg/mL, oil volume and crash/PIP risk become the limiting factor more than dose itself.
Kickstart bridge. Cypionate's slow onset means meaningful effect often does not appear until week 3-4. Users frequently report short oral or short-ester kickstarts for the first 4 weeks, but this adds hepatic and cardiovascular burden and is an observed practice rather than a default instruction.
PCT context. Non-TRT users commonly plan SERM PCT around the 2.5-3 week cypionate washout. Users on cruising or TRT usually return to baseline testosterone replacement after washout. This is high-risk endocrine management and should not be treated as reader-specific dosing advice.
Dose-titration logic. Most experienced users do not push above 500 mg per week on subsequent cycles because hsCRP, hematocrit, BP, and PIP burden scale faster than payoff. The observed failure mode is quitting mid-cycle from pain or inflammation, not outgrowing the dose.
Stacks & Alternatives
Mandatory base. Dihydroboldenone does not aromatize and cannot provide E2-mediated libido, joint, or cardiovascular support. Standard dose 150-300 mg per week alongside DHB.
Frequently stacked at 300-400 mg per week for additive dry-physique signature. Some users prefer the combo because it doubles the aesthetic effect without adding AR-overlap concerns that trenbolone would create. Cost is the limiting factor.
Also DHT-class, also non-aromatizing. Stacked at 400-600 mg per week for hardening and pre-contest aesthetic. AR-saturation overlap is real but less than with trenbolone.
Heavily stacked in advanced cycles, typically at 200-400 mg per week alongside 300-500 mg DHB. Community framing acknowledges trenbolone overshadows the DHB effect at moderate doses — choose this stack accepting that trenbolone is the primary driver.
50 mg per day for the final 6-8 weeks of cycle as a finisher. Adds strength endurance and additional hardness without injecting more oil. Liver values warrant attention.
Kickstart at 40-60 mg per day for weeks 1-4 to bridge cypionate ester's slow onset. Standard practice for any cypionate-based cycle.
Alternative kickstart at 25-30 mg per day weeks 1-4. More aggressive than Tbol, higher water retention (which the DHB framing tries to avoid), but cheap and reliable.
250-500 IU 2x weekly during cycle to maintain testicular size and downstream upstream signaling. Standard supportive practice for any suppressive cycle.
Dosed off the testosterone base only — DHB itself does not aromatize. Calibrate by sensitive E2 bloodwork, not by symptom.
3-6 IU per day in advanced cycles. Synergizes with AAS for recomp and tissue quality. Independent of DHB pharmacology but commonly co-administered.
Alternatives
Stack Cost
Dihydroboldenone demands substantial monitoring infrastructure, occupies the AR-driver slot, forces injection-site rotation and PIP management, and produces inflammatory and cardiovascular drift that crowds out same-lane compounds.
Suppresses LH/FSH and endogenous testosterone production at all therapeutic doses. PCT mandatory for non-TRT users; 2.5-3 week washout before SERM start due to cypionate ester clearance.
Documented rodent hepatotoxicity, predictable lipid skew (HDL down, LDL/total cholesterol up), hematocrit elevation, and BP drift consistent with DHT-class. Requires hsCRP, lipid panel, CBC, BP monitoring at baseline and midcycle; HDL below 30 or hematocrit above 54% are dose-reduction triggers.
Subset of users develop mood flatness, depression, or in rare cases active suicidal ideation within 1-4 weeks even at modest doses. Mechanism poorly characterized — possibly CRP-driven cytokine effects on CNS. Highly unpredictable; cannot pre-screen susceptibility.
Severe PIP at most injection sites, requires concentration ceiling 75-100 mg/mL, formulation handling discipline due to high melting point crashing, site rotation across 4-6 sites weekly to avoid induration buildup. Single-shot oil volume becomes the limiting factor on tolerability.
Recommended panels span CBC, full lipid, hsCRP, CMP, LFTs, post-cycle hormone panel, and ongoing BP — substantially heavier monitoring infrastructure than most AAS. Users without lab access should not run this compound.
- ·Occupies the primary AR-driver slot — do not stack at full doses with trenbolone (overlapping AR saturation, additive CRP/BP/CNS burden).
- ·Mandates a testosterone base of 150-300 mg/week — DHB cannot replace testosterone because it does not aromatize.
- ·Maximum two DHT-class compounds at full doses in a stack (e.g., DHB + Masteron or DHB + Primobolan); three is excessive.
- ·Methylated orals used only as 4-6 week kickstart, not full-cycle co-administration, due to combined hepatic load.
- ·Cycle length minimum 10 weeks for cypionate ester kinetics; cycles under 10 weeks waste the PIP burden without delivering the gain.
- ·Baseline + midcycle hsCRP, CBC, full lipid panel, CMP, LFTs — at minimum 2 panels per cycle plus a post-cycle panel.
- ·Home blood pressure cuff for ongoing monitoring; multiple daily readings during cycle.
- ·Formulation-quality and injection-log tracking for PIP patterns.
- ·Site-rotation discipline across 4-6 injection sites on a weekly cycle.
- ·Supportive supplements: omega-3 (3-4 g EPA+DHA), citrus bergamot, NAC or TUDCA for hepatic protection, possible ezetimibe or telmisartan based on bloodwork.
Unpredictable individual response (mood, PIP severity, CRP magnitude), heavy monitoring infrastructure, high injection-logistics burden, and high counterfeit/substitution risk make DHB advanced-only.
- ·First or second cycle ever
- ·No access to bloodwork infrastructure
- ·Documented baseline hsCRP elevation (above 3 mg/L) or chronic inflammatory condition
- ·History of mood disorders, depression, or anxiety
- ·Active male-pattern hair loss progression without topical antiandrogen access
Cypionate ester clearance takes 2.5-3 weeks before SERM PCT can start. HPG axis recovery follows standard timeline (8-16 weeks for full restart in non-TRT users). Hematocrit and lipids normalize within 4-8 weeks post-cycle in most users. Mood effects, if present, typically resolve within 2-4 weeks of discontinuation.
- ·Loss of dry-physique aesthetic within 2-3 weeks as water retention returns alongside resumed testosterone production
- ·Temporary mood drop during ester clearance + PCT window (weeks 2-6 post-cycle)
- ·Slow HPG axis recovery in users running cycles longer than 16 weeks or pushing high doses
- ·Persistent hairline recession that does not reverse
- ·Possible persistent CRP elevation in users who pushed through midcycle CRP rises rather than discontinuing
Keep concentration and oil volume conservative, avoid repeated same-site stress, and discontinue or change course if PIP severity exceeds tolerability after several attempts.
Discontinue immediately on any of these signals. The mood effect does not resolve through tolerance — continuing exposure typically worsens it. Mood typically returns to baseline within 2-4 weeks of discontinuation.
Discontinuation is the most reliable response. Dose reduction may help in some users but if hsCRP elevation is consistent across doses, the compound is not a fit for this individual.
Therapeutic phlebotomy or blood donation to bring hematocrit below 50%; concurrent dose reduction 25-30% or discontinuation. ARB (telmisartan, losartan) for BP if persistent.
Personal androgen sensitivity is uncharacterized; PIP tolerance unknown; mood variability cannot be pre-screened; PCT competence not established.
Mood-flatness side effect of DHB is unpredictable but disproportionately appears in users with prior mood vulnerability. The risk-benefit balance does not favor use in this context.
DHB's CRP-elevation signal is compound-intrinsic. Users with baseline inflammation see midcycle hsCRP clear 20-30 mg/L commonly, with associated flu-like malaise.
Finasteride cannot protect; DHB drives AR activation at scalp directly. Hairline loss during DHB cycles is rapid and not fully reversible.
Practical Setup
Sourcing and authenticity. Consistent DHB cypionate batch quality is limited. Boldenone (equipoise) adulteration is the most common counterfeit substitution.
PIP-absent dihydroboldenone is treated in community discussion as a likely substitution signal. Product identity and batch consistency dominate outcomes more than dose selection.
Formulation fragility. Dihydroboldenone cypionate is prone to crystallizing out of carrier oil because its melting point sits close to the smoke point of common carrier oils. Reports often mention warming the oil to reduce crash-related PIP, but that is a formulation-quality workaround rather than a safety guarantee.
Route burden. Site selection, repeated same-site stress, oil volume, concentration, and formulation quality drive much of DHB's tolerability burden. Community reports describe larger injection sites as better tolerated than quadriceps, but those details are operational and not a substitute for sterile medical technique.
Drug interactions. CYP3A4 inhibitors (grapefruit, ketoconazole, ritonavir, clarithromycin) can elevate DHB serum levels unpredictably. CYP3A4 inducers (St. John's Wort, rifampin) drop serum levels. Chronic medications affecting CYP3A4 make DHB a clinician-context decision rather than a casual protocol. Supplement interactions are also significant — berberine, curcumin, grapefruit extract, and several others affect CYP3A4 in conflicting directions.
Signs protocol adjustment is needed. Hematocrit clearing 52% is a warning context; hematocrit above 54% is a dose-reduction or discontinuation signal. hsCRP above 10 mg/L without alternative explanation points toward discontinuation because the inflammatory load may be the compound itself. Blood pressure sustained above 140/90, HDL below 30 mg/dL, LDL above 160 mg/dL, or mood flatness/depression within the first 4 weeks are not signals to push through.
Practical tracking. Responsible reports treat pre-cycle bloodwork, midcycle bloodwork, blood-pressure tracking, PIP/systemic-symptom logging, and post-cycle hormone follow-up as part of the burden. Supportive lipid, inflammation, liver, and blood-pressure aids are common in experienced-user reports, but they do not make DHB beginner-friendly.
Discontinuation timeline. Cypionate ester clearance takes approximately 2.5-3 weeks for serum levels to drop below biologically significant thresholds. PCT timing for non-TRT users is built around that washout. Symptoms typically begin returning toward baseline 2-4 weeks into recovery, with full HPG recovery taking 8-16 weeks depending on cycle length and individual response.
Mechanism Deep Dive
Androgen receptor binding and activity. Dihydroboldenone binds the androgen receptor with potency comparable to testosterone.
The Friedel et al. 2006 toxicology paper characterized this AR binding affinity in vivo with androgenic activity 'similar to testosterone but without estrogenic effects due to lack of aromatization.' The 200:100 anabolic-to-androgenic ratio frequently cited in community discussion originates from rodent assays measuring levator ani muscle weight gain (anabolic index) vs. ventral prostate weight gain (androgenic index). Critical editorial coverage (Pruski) pushes back on direct translation of these ratios to human dose-response, noting that rodent ratio assays do not reliably predict tissue selectivity at human therapeutic-scale doses.
5α-reduced structure and consequences. Dihydroboldenone is the 5α-reduced metabolite of boldenone, structurally analogous to how dihydrotestosterone is the 5α-reduced metabolite of testosterone. The compound differs from testosterone by replacing testosterone's 4(5)-double bond with a 1(2)-double bond in the A ring. This structural feature has three downstream consequences:
— No aromatization. The 5α-reduced structure eliminates the substrate geometry required for aromatase action. DHB cannot convert to estradiol or other estrogenic metabolites, so estradiol management during cycle is driven entirely by the testosterone base dose, not by DHB.
— No further 5α-reduction. DHB is already past the 5α-reductase step. Finasteride and dutasteride inhibit 5α-reductase, but the enzyme has nothing to do to a molecule that is already 5α-reduced. This is why scalp protection from 5αR-inhibitors fails on DHB cycles — the compound can directly activate the AR at hair follicles without any 5α-reduction step that finasteride could block.
— DHT-class tissue distribution. 5α-reduced androgens distribute to androgen-target tissues with the same kinetics as endogenous DHT — high in skin, scalp, prostate, and AR-rich muscle tissue. The 'dry, hard, vascular' aesthetic users describe corresponds to AR activation in these tissues without water-retention pathways activated by E2 elsewhere.
Cypionate ester pharmacokinetics. The cypionate ester (cyclopentylpropionate) hydrolyzes slowly via plasma and tissue esterases, releasing free dihydroboldenone with a half-life of approximately 8 days. Peak serum concentrations are reached at 48 hours post-injection, with active duration approximately 192 hours. Steady-state requires 4-5 weeks at standard pinning intervals. This slow onset is the kinetic reason kickstart compounds (Tbol, Anavar, testosterone propionate) are commonly added for weeks 1-4 of a cypionate-based cycle.
HPG axis suppression. Standard for any AR-active compound at supraphysiologic doses. DHB suppresses LH and FSH via negative feedback at the hypothalamus and pituitary, with downstream suppression of endogenous testosterone production. The suppression is comparable in magnitude to equimolar doses of testosterone or trenbolone. Recovery on PCT follows standard SERM-stimulated patterns over 8-16 weeks.
CRP elevation and systemic inflammation. The mechanism is incompletely characterized. Community discussion attributes the CRP rise to the compound itself or its metabolites, not solely to carrier oil reactions. One hypothesis is that DHT-class androgens at supraphysiologic doses modulate macrophage and hepatocyte cytokine signaling, increasing IL-6 production which drives hepatic CRP synthesis. The clinical manifestation — flu-like malaise, fatigue, low-grade fever — appears in a subset of users and tracks the CRP rise. The mechanism is also potentially related to local PIP/inflammation seeding systemic IL-6 release, but community evidence suggests it persists even in users with minimal local PIP.
Hematocrit elevation. DHT-class androgens reliably increase erythropoietin production and bone marrow erythroid activity. Hematocrit drifts upward during DHB cycles consistent with this mechanism. Practical consequence: midcycle hematocrit above 52% should trigger therapeutic phlebotomy or donation consideration; above 54% should trigger dose reduction or discontinuation due to viscosity and BP risk.
Boldenone-to-DHB conversion (endogenous). Boldenone is a 5α-reductase substrate. Approximately 2-4% of boldenone systemic exposure converts to dihydroboldenone endogenously, with conversion being route-independent (oral or injectable, same rate). Conversion is enriched in scalp tissue where local 5α-reductase activity is high. This explains why high-dose equipoise users (e.g., 1,000-1,500 mg per week) experience some DHB-like effects despite running the parent compound; it also explains why EQ users with male-pattern hair loss susceptibility see frontal hairline issues even at moderate doses. Mega-dosing EQ to achieve indirect DHB serum levels (1,250 mg EQ per week yields ~150 mg DHB free) is documented but inefficient compared to direct DHB dosing.
Hepatotoxicity mechanism. Rodent studies document hepatic toxicity at high doses. While injectable AAS skip first-pass hepatic metabolism, systemic recirculation through hepatic CYP3A4 still produces hepatic exposure. The specific mechanism — oxidative stress, AR-mediated hepatocyte effects, or metabolite toxicity — is not characterized in published human literature. LFT monitoring at baseline and midcycle is prudent based on the rodent signal.
Experimental PFS recovery mechanism. The dihydroboldenone + sodium valproate post-finasteride syndrome recovery protocol — community-described as a 'eureka moment' — operates on a specific hypothesis: post-finasteride syndrome involves persistent AR underactivity in 5α-reduced tissues (scalp, skin, CNS) due to neurosteroid pathway disruption. DHB delivers AR activation in those tissues without re-engaging the 5α-reductase pathway (which finasteride users may have permanently altered). Sodium valproate functions as a histone deacetylase (HDAC) inhibitor and GABAergic modulator, hypothetically restoring epigenetic AR expression and neurosteroid balance. The protocol intentionally excludes testosterone because re-introducing T would re-engage 5α-reductase. This mechanism remains experimental — no clinical trial has tested it — and the protocol falls well outside standard dihydroboldenone use cases.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
DHB binds the androgen receptor with potency comparable to testosterone without estrogenic effects due to lack of aromatization.
Friedel et al. Toxicology Letters 2006 — AR binding affinity characterization. Translation to human therapeutic doses is community-inferred, not clinically established.
DHB has anabolic:androgenic ratio of 200:100.
Origin of the 200:100 ratio is rodent organ-weight assay. Critical editorial (Pruski) notes these ratios do not reliably predict human tissue selectivity.
Users running 300-500 mg per week on a testosterone base of 150-300 mg per week report dry, hard, vascular physique changes at week 4-6, peak at week 8-10.
Aggregated from multiple community logs. No controlled trial data. Individual response variability is high.
Cypionate ester half-life is ~8 days; peak at 48 hours; active duration ~192 hours; steady-state at 4-5 weeks.
Cypionate ester pharmacokinetics are well-established across AAS class; specific human DHB cypionate PK data is not published.
Tolerable injection concentrations are 75-100 mg/mL; above 200 mg/mL is universally intolerable.
Empirical community consensus across multiple community discussions. Some users tolerate 150 mg/mL (high-concentration) with vial warming; mechanism is melting-point/crash-resistance related.
Mood flatness, depression, or active suicidal ideation appears in subset of users within 1-4 weeks at doses as low as 200 mg per week.
Aggregated 2024 community reports. Mechanism uncharacterized. Prevalence within total user population is not quantifiable from available data.
Boldenone conversion to DHB is approximately 2-4%, route-independent.
local local corpus assertion (certainty 0.6). No published clinical conversion data for boldenone-to-DHB in humans.
DHB cypionate melts at 192-196°C, among the highest melting points of injectable AAS esters.
Empirical melting point measurement from steroid chemistry literature and brewing community references.
Hepatotoxicity is documented in rodent studies.
Cited in AAS editorial editorial review of available DHB literature. Specific rodent paper attribution is not preserved in the retained evidence.
Standard cycle length is 10-16 weeks; cycles shorter than 10 weeks deliver only 5 weeks of saturated steady-state.
Aggregated cycle-guide and community practice. Kinetics-driven recommendation.
PCT protocol: Nolvadex 40/40/20/20 mg per day or Clomid 50/50/25/25 mg per day, starting 2.5-3 weeks after last cypionate pin.
Standard SERM PCT for cypionate-ester cycles. Biomogging guide is the cited source; consistent with broader community PCT consensus.
Dose range across community users is 200-700 mg/week, with 300-500 mg/week as the most common sweet spot.
Aggregated from multiple bodybuilding-community reports and practitioner guides. Wide individual variability noted: '600 and have to stop from sides, 400 with great results, or 300 with no results.'
Material cost is $300-720 for a 10-16 week cycle at 300-500 mg per week.
Pricing varies by region, source, and batch; use only as rough cost context, not an access guide.
Mega-dosing EQ at 1,250 mg per week yields approximately 150 mg per week free DHB equivalent.
local local corpus assertion (certainty 0.5). Derived from 2-4% boldenone-to-DHB conversion estimate; not clinically validated.
Menstrual disruption typically appears within 2-4 weeks at therapeutic doses.
Inferred from DHT-class androgen pharmacology; no female-specific DHB human data exists. Practitioner consensus treats menstrual disruption as the first virilization signal across the class.
5α-reduced structure means dihydroboldenone cannot be further reduced by 5α-reductase and cannot be blocked by finasteride at the scalp.
Established mechanism of 5α-reductase inhibition: finasteride inhibits an enzyme upstream of DHB; DHB is already past the enzymatic step.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.